Immunic Inc (IMUX)

Mar 12, 2025

Immunic at Leerink’s Conference: Strategic Moves in MS Treatment - Investing.com

Mar 12, 2025

Mar 11, 2025

Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April - Proactive financial news

Mar 11, 2025

Mar 10, 2025

Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World

Mar 10, 2025

Mar 06, 2025

Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Analysts - Defense World

Mar 06, 2025

Mar 05, 2025

Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data - Proactive Investors

Mar 05, 2025

Mar 04, 2025

Immunic to Participate in Scientific and Investor Conferences in March - Kilgore News Herald

Mar 04, 2025

Mar 03, 2025

Immunic announces participation in Hamburg and Miami conferences - Proactive Investors USA

Mar 03, 2025

Mar 03, 2025

Immunic Showcases Dual-Action Drug Research at Major Virology Meeting While Courting Investors - StockTitan

Mar 03, 2025

Mar 01, 2025

Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Mar 01, 2025

Feb 28, 2025

D. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat

Feb 28, 2025

Feb 28, 2025

Biotechs challenge big pharma with new oral weight loss therapies - Proactive Investors USA

Feb 28, 2025

Feb 26, 2025

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis - The Malaysian Reserve

Feb 26, 2025

Feb 26, 2025

Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum - Proactive Investors USA

Feb 26, 2025

Feb 25, 2025

Immunic (NASDAQ:IMUX) Receives Buy Rating from HC Wainwright - MarketBeat

Feb 25, 2025

Feb 24, 2025

How Do Things Look For Immunic Inc (NASDAQ: IMUX) In The Short-Term? - Stocks Register

Feb 24, 2025

Feb 24, 2025

Immunic's (IMUX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Feb 24, 2025

Feb 23, 2025

Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World

Feb 23, 2025

Feb 22, 2025

Immunic (IMUX) to Release Earnings on Thursday - MarketBeat

Feb 22, 2025

Feb 22, 2025

Immunic drug candidate may offer new obesity treatmentICYMI - Proactive Investors USA

Feb 22, 2025

Feb 22, 2025

Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week - Yahoo Finance

Feb 22, 2025

Feb 21, 2025

H.C. Wainwright maintains Immunic stock Buy rating, $10 target By Investing.com - Investing.com Nigeria

Feb 21, 2025

Feb 21, 2025

H.C. Wainwright maintains Immunic stock Buy rating, $10 target - Investing.com

Feb 21, 2025

Feb 21, 2025

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing - The Malaysian Reserve

Feb 21, 2025

Feb 20, 2025

Market movers: Walmart, Palantir, Immunic, Alibaba… - Proactive Investors UK

Feb 20, 2025

Feb 20, 2025

Immunic’s IMU-856 shows promise in weight management By Investing.com - Investing.com Nigeria

Feb 20, 2025

Feb 20, 2025

Immunic highlights IMU-856’s potential as weight management therapy - Proactive Investors Australia

Feb 20, 2025

Feb 20, 2025

Immunic's IMU-856 shows promise in weight management - Investing.com

Feb 20, 2025

Feb 20, 2025

Immunic’s IMU-856 shows promise for obesity treatment - Proactive Investors USA

Feb 20, 2025

Feb 20, 2025

Immunic's IMU-856 shows promise in weight management By Investing.com - Investing.com South Africa

Feb 20, 2025

Feb 20, 2025

Immunic announces IMU-856 demonstrated dose-dependent increase - TipRanks

Feb 20, 2025

Feb 20, 2025

Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1 -February 20, 2025 at 07:31 am EST - Marketscreener.com

Feb 20, 2025

Feb 19, 2025

Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat

Feb 19, 2025

Feb 19, 2025

Pleasing Signs As A Number Of Insiders Buy Immunic Stock - Simply Wall St

Feb 19, 2025

Feb 18, 2025

Immunic Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

Feb 18, 2025

Feb 15, 2025

Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by StockNews.com - MarketBeat

Feb 15, 2025

Feb 12, 2025

IMUX stock touches 52-week low at $0.92 amid market challenges - MSN

Feb 12, 2025

Feb 11, 2025

Breaking Barriers: Immunic CSO marks International Day of Women and Girls in Science - Proactive Investors USA

Feb 11, 2025

Feb 09, 2025

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Brokerages - MarketBeat

Feb 09, 2025

Feb 07, 2025

Immunic CEO on key MS trial data coming in April - Proactive Investors USA

Feb 07, 2025

Feb 05, 2025

Immunic Inc (IMUX) Becoming More Attractive for Investors - Knox Daily

Feb 05, 2025

Feb 05, 2025

Immunic Inc’s results are impressive - US Post News

Feb 05, 2025

Feb 05, 2025

Market Recap: Immunic Inc (IMUX)’s Negative Momentum, Closing at 0.95 - The Dwinnex

Feb 05, 2025

Feb 05, 2025

Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in January - MarketBeat

Feb 05, 2025